Table 1. Clinical and biologic data .... | American Society of Hematology

Table 1.

Clinical and biologic data

	Patient 1	Patient 2	Patient 3
Age (y)	29	62	51
Sex	Female	Female	Male
Indication of SU5416 therapy	Retinal Hb	Cervical Hb	Cerebellar Hb
Other VHL manifestations	Quiescent cerebellar Hb	Quiescent cerebellar Hb	Small renal tumor
	Renal and pancreatic cysts	Renal and pancreatic cysts	Renal and pancreatic cysts
Hematocrit (%)/hemoglobin (g/L)
Before SU5416 therapy	39/12.3	45/14.9	50/16.6
After SU5416 therapy^*	51/16.3^†	53/17.2^†	56/18.4^‡
Red blood cell mass (mL/kg)^†	32.2	36.4	37.7
Variation of globular volume	+ 26%	+ 28%	+ 28%
Erythropoietin (N: 5-25 mU/mL)
Before SU5416 therapy	2.0	2.0	10.0
After 12 weeks of drug	1.9	2.6	8.0
Assessment of VHL tumors after 12 weeks of drug	Stable	Stable	Stable
Interruption of drug	No	No	No
Treatment of polycythemia	Bloodletting (1 × 300 mL)	Bloodletting (3 × 300 mL)	Bloodletting (2 × 300 mL)
Recurrence of polycythemia	No	No	No

	Patient 1	Patient 2	Patient 3
Age (y)	29	62	51
Sex	Female	Female	Male
Indication of SU5416 therapy	Retinal Hb	Cervical Hb	Cerebellar Hb
Other VHL manifestations	Quiescent cerebellar Hb	Quiescent cerebellar Hb	Small renal tumor
	Renal and pancreatic cysts	Renal and pancreatic cysts	Renal and pancreatic cysts
Hematocrit (%)/hemoglobin (g/L)
Before SU5416 therapy	39/12.3	45/14.9	50/16.6
After SU5416 therapy^*	51/16.3^†	53/17.2^†	56/18.4^‡
Red blood cell mass (mL/kg)^†	32.2	36.4	37.7
Variation of globular volume	+ 26%	+ 28%	+ 28%
Erythropoietin (N: 5-25 mU/mL)
Before SU5416 therapy	2.0	2.0	10.0
After 12 weeks of drug	1.9	2.6	8.0
Assessment of VHL tumors after 12 weeks of drug	Stable	Stable	Stable
Interruption of drug	No	No	No
Treatment of polycythemia	Bloodletting (1 × 300 mL)	Bloodletting (3 × 300 mL)	Bloodletting (2 × 300 mL)
Recurrence of polycythemia	No	No	No

Hb, hemangioblastoma.

Maximal value of hematocrit;

after 16 weeks of drug;

after 12 weeks of drug.